Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit
Objective:Pneumothorax (PNX) and subcutaneous emphysema (SCE) have increased in importance as a frequently occurring complication. This study aimed to reveal the frequency, timing, and possible risk factors in patients with PNX and SCE who are followed up with coronavirus disease-2019 (COVID-19) diagnosis in our tertiary intensive care unit (ICU).Materials and Methods:All patients with confirmed COVID-19 who were followed up and treated in our unit between August 8, 2020, and February 20, 2021, in a 16-bed tertiary ICU and who developed PNX and SCE during their hospitalization were included.Results:PNX and SCE developed in 16 (9.6%) of 165 patients who were followed up in our ICU due to COVID-19. Of these 16 patients, 3 (18.8%) survived. The median age of patients was 66.5 years (interquartile range: 58.5-75.5). Diabetes mellitus was the most common comorbidity in patients with PNX and SCE. Additionally, 12 (75%) patients had a smoking history. Of 15 (93.8%) patients who developed PNX, 4 (25%) were bilateral, and SCE developed in 9 (56.3%) patients. Twelve (75%) patients with PNX and SCE were under invasive mechanical ventilation, 3 (18.8%) under spontaneous breathing, and 1 (6.2%) under non-invasive mechanical ventilation treatment. The number of oxygen support days until the time PNX and SCE developed was 9 (6.25-17) days in the whole group, the median time was 6 days in the survival group and 9 days in the non-survival group.Conclusion:In the COVID-19 pandemic, complications, such as PNX and SCE, are more frequently observed (9.5%) than in the general intensive care population and the later period of intensive care admission (median 9 days). Smoking is defined as a risk factor in most of these patients; however, increased PNX rates are thought to be related to both COVID-19 pneumonia and parenchymal damage due to cytokine storms..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Türk Yoğun Bakim Derneği Dergisi - 19(2021), 1, Seite 95-101 |
| Sprache: |
Englisch ; Türkisch |
|---|
| Beteiligte Personen: |
Mehtap Pehlivanlar Küçük [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.4274/tybd.galenos.2021.30316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ072858885 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ072858885 | ||
| 003 | DE-627 | ||
| 005 | 20230310185128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4274/tybd.galenos.2021.30316 |2 doi | |
| 035 | |a (DE-627)DOAJ072858885 | ||
| 035 | |a (DE-599)DOAJ657357bd471541aca3d6816283f2e60c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a tur | ||
| 050 | 0 | |a RC31-1245 | |
| 050 | 0 | |a RC86-88.9 | |
| 100 | 0 | |a Mehtap Pehlivanlar Küçük |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pneumothorax and Subcutaneous Emphysema Evaluation in Patients with COVID-19 in the Intensive Care Unit |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective:Pneumothorax (PNX) and subcutaneous emphysema (SCE) have increased in importance as a frequently occurring complication. This study aimed to reveal the frequency, timing, and possible risk factors in patients with PNX and SCE who are followed up with coronavirus disease-2019 (COVID-19) diagnosis in our tertiary intensive care unit (ICU).Materials and Methods:All patients with confirmed COVID-19 who were followed up and treated in our unit between August 8, 2020, and February 20, 2021, in a 16-bed tertiary ICU and who developed PNX and SCE during their hospitalization were included.Results:PNX and SCE developed in 16 (9.6%) of 165 patients who were followed up in our ICU due to COVID-19. Of these 16 patients, 3 (18.8%) survived. The median age of patients was 66.5 years (interquartile range: 58.5-75.5). Diabetes mellitus was the most common comorbidity in patients with PNX and SCE. Additionally, 12 (75%) patients had a smoking history. Of 15 (93.8%) patients who developed PNX, 4 (25%) were bilateral, and SCE developed in 9 (56.3%) patients. Twelve (75%) patients with PNX and SCE were under invasive mechanical ventilation, 3 (18.8%) under spontaneous breathing, and 1 (6.2%) under non-invasive mechanical ventilation treatment. The number of oxygen support days until the time PNX and SCE developed was 9 (6.25-17) days in the whole group, the median time was 6 days in the survival group and 9 days in the non-survival group.Conclusion:In the COVID-19 pandemic, complications, such as PNX and SCE, are more frequently observed (9.5%) than in the general intensive care population and the later period of intensive care admission (median 9 days). Smoking is defined as a risk factor in most of these patients; however, increased PNX rates are thought to be related to both COVID-19 pneumonia and parenchymal damage due to cytokine storms. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a pneumothorax | |
| 650 | 4 | |a intensive care unit | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Internal medicine | |
| 653 | 0 | |a Medical emergencies. Critical care. Intensive care. First aid | |
| 700 | 0 | |a Burcu Öksüz Güngör |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmet Oğuzhan Küçük |e verfasserin |4 aut | |
| 700 | 0 | |a Olcay Ayçiçek |e verfasserin |4 aut | |
| 700 | 0 | |a Atila Türkyılmaz |e verfasserin |4 aut | |
| 700 | 0 | |a Funda Öztuna |e verfasserin |4 aut | |
| 700 | 0 | |a Yılmaz Bülbül |e verfasserin |4 aut | |
| 700 | 0 | |a Tevfik Özlü |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Türk Yoğun Bakim Derneği Dergisi |d Galenos Yayinevi, 2015 |g 19(2021), 1, Seite 95-101 |w (DE-627)DOAJ000019054 |x 2147267X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:1 |g pages:95-101 |
| 856 | 4 | 0 | |u https://doi.org/10.4274/tybd.galenos.2021.30316 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/657357bd471541aca3d6816283f2e60c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.turkishjic.org/archives/archive-detail/article-preview/pneumothorax-and-subcutaneous-emphysema-evaluation/50666 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2146-6416 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2147-267X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 1 |h 95-101 | ||